Table 2.
Complications, treatments and outcomes of patients.
| No. (%) | p value | |||
|---|---|---|---|---|
|
| ||||
| Total N=118 | Treatment group N=33 | Control group N=85 | ||
| Complications | ||||
| ARDS | 66(55.8) | 12(36.3) | 54(63.5) | 0.012 |
| Liver dysfunction | 18(14.2) | 4(12.1) | 14(16.4) | 0.555 |
| Acute kidney injury | 36(30.5) | 8(24.2) | 28(32.9) | 0.357 |
| Cardiac injury | 37(31.3) | 5(15.1) | 32(37.6) | 0.026 |
| Coagulopathy | 29(24.5) | 9(27.2) | 20(23.5) | 0.812 |
| Shock | 27(22.8) | 5(15.1) | 22(25.8) | 0.328 |
| Treatments | ||||
| High-flow nasal cannula oxygen therapy | 20(16.9) | 9(27.2) | 11(12.9) | 0.098 |
| Mechanical ventilation | 94(79.6) | 22(66.7) | 72(84.7) | 0.028 |
| Non-invasive | 23(19.3) | 4(12.1) | 19(22.3) | 0.301 |
| Invasive | 71(60.1) | 18(54.5) | 53(62.3) | 0.436 |
| ECMO | 5(4.2) | 2(6.0) | 3(3.5) | 0.618 |
| Antiviral therapy | 71(60.1) | 21(63.6) | 50(58.8) | 0.679 |
| Antibiotics | 112(94.8) | 31(93.9) | 82(95.2) | 0.671 |
| Glucocorticoid therapy | 92(77.9) | 24(72.7) | 68(80) | 0.459 |
| Renal replacement therapy | 23(19.4) | 7(21.2) | 16(18.8) | 0.798 |
| Outcomes | ||||
| Discharged from ICU | 29(24.5) | 14(42.4) | 15(17.6) | 0.008 |
| Died in ICU | 83(70.3) | 15(45.4) | 68(80.0) | 0.0002 |
| Still in ICU as of 4/22/2020a | 6(5.2) | 4(12.2) | 2(2.4) | 0.051 |
| Length of ICU stay at study end pointb | ||||
| Died, median (IQR) (d) | 9(6-17) | 18(12-30) | 9(6-13) | 0.0002 |
| Discharged alive, median (IQR), (d) | 67(27-76) | 32(20-73) | 76(63-79) | 0.0074 |
Abbreviations: ICU, intensive care unit; ARDS, acute respiratory distress syndrome;
ECMO, extracorporealmembrane oxygenation; IQR, interquartile range.
aPatients were admitted between 1/28/2020 and 3/28/2020, with follow-up through 4/22/2020.
bLength of stay begins with admission time and ends with discharge time, time at death, or on the last day of data collection for the study.
Boldface values were considered statistically significant.